TLR3 in Human Eosinophils: Functional Effects and Decreased Expression during Allergic RhinitisMånsson A.a · Fransson M.a · Adner M.a · Benson M.c · Uddman R.a · Björnsson S.b · Cardell L.-O.d
aLaboratory of Clinical and Experimental Allergy Research, Department of Otorhinolaryngology and bDepartment of Clinical Chemistry, Malmö University Hospital, Lund University, Malmö, cDepartment of Pediatrics, Queen Silvia Children’s Hospital, Sahlgrenska University Hospital, Gothenburg, and dDivision of ENT Diseases Huddinge, Karolinska Institutet, Stockholm, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aim: Viral respiratory infections are increasingly implicated in allergic exacerbations. Virus-induced activation of eosinophils through Toll-like receptors (TLRs) could be involved. The present study was designed to examine TLR3 expression in eosinophils from bone marrow (BM) and peripheral blood (PB) during symptomatic allergic rhinitis, and to evaluate the functional responsiveness of TLR3 in purified eosinophils. Methods: BM and PB samples were obtained from healthy volunteers and patients with seasonal allergic rhinitis outside and during the pollen season. Eosinophils were analyzed for TLR3 expression by flow cytometry. Polyinosinic:polycytidylic acid [poly(I:C)], an agonist for TLR3, was used to assess its functional role in purified eosinophils and the intracellular signaling pathways involved. Results: TLR3 expression was demonstrated in BM and PB eosinophils. It was higher in BM-derived than in circulating cells and it was downregulated in both compartments during symptomatic allergic rhinitis. TLR3 expression was also downregulated in the presence of interleukin (IL)-4 and IL- 5. Stimulation with poly(I:C) increased the percentage of CD11b+ cells and enhanced the secretion of IL-8, effects mediated via the p38 mitogen-activated protein kinases and nuclear factor-ĸB signaling pathways. Moreover, pretreatment with IL-5 augmented the poly(I:C)-induced IL-8 release. Conclusions: Eosinophils activated via TLR3 might be more able to home and recruit leukocytes to sites of inflammation. The decreased TLR3 expression during symptomatic allergic rhinitis and in the presence of Th2 cytokines indicates a role in allergic airway inflammation. Thus, eosinophils might function as a link between viral infections and exacerbations of allergic disease.
© 2009 S. Karger AG, Basel
- Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME: Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709–750.
- Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I: Eosinophils in asthma and other allergic diseases. Br Med Bull 2000;56:985–1003.
- van Rijt LS, van Kessel CH, Boogaard I, Lambrecht BN: Respiratory viral infections and asthma pathogenesis: a critical role for dendritic cells? J Clin Virol 2005;34:161–169.
- Contoli M, Caramori G, Mallia P, Johnston S, Papi A: Mechanisms of respiratory virus-induced asthma exacerbations. Clin Exp Allergy 2005;35:137–145.
- Iwasaki A, Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987–995.
- Akira S, Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85–95.
- Abreu MT, Arditi M: Innate immunity and Toll-like receptors: clinical implications of basic science research. J Pediatr 2004;144:421–429.
- Fransson M, Benson M, Erjefalt JS, Jansson L, Uddman R, Bjornsson S, Cardell LO, Adner M: Expression of Toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. Respir Res 2007;8:17.
- Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, Hirai K: Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 2003;171:3977–3982.
- Plotz SG, Lentschat A, Behrendt H, Plotz W, Hamann L, Ring J, Rietschel ET, Flad HD, Ulmer AJ: The interaction of human peripheral blood eosinophils with bacterial lipopolysaccharide is CD14 dependent. Blood 2001;97:235–241.
- Sabroe I, Jones EC, Usher LR, Whyte MK, Dower SK: Toll-like receptor (TLR) 2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol 2002;168:4701–4710.
- Wong CK, Cheung PF, Ip WK, Lam CW: Intracellular signaling mechanisms regulating Toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol 2007;37:85–96.
- Cheung PF, Wong CK, Ip WK, Lam CW: FAK-mediated activation of ERK for eosinophil migration: a novel mechanism for infection-induced allergic inflammation. Int Immunol 2008;20:353–363.
- Mansson A, Cardell LO: Role of atopic status in Toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophils. J Leukoc Biol 2009;85:719–727.
- Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, Foster PS, Matthaei KI: Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 2007;110:1578–1586.
- Hayashi F, Means TK, Luster AD: Toll-like receptors stimulate human neutrophil function. Blood 2003;102:2660–2669.
- Bryborn M, Adner M, Cardell LO: Interleukin-4 increases murine airway response to kinins, via up-regulation of bradykinin B1-receptors and altered signalling along mitogen-activated protein kinase pathways. Clin Exp Allergy 2004;34:1291–1298.
- Ekman AK, Fransson M, Rydberg C, Adner M, Cardell LO: Nasal challenge with LPS stimulates the release of macrophage inflammatory protein 1α. Int Arch Allergy Immunol 2009;149:154–160.
- Terstappen LW, Mickaels RA, Dost R, Loken MR: Increased light scattering resolution facilitates multidimensional flow cytometric analysis. Cytometry 1990;11:506–512.
- Gopinath R, Nutman TB: Identification of eosinophils in lysed whole blood using side scatter and CD16 negativity. Cytometry 1997;30:313–316.
- Mansson A, Adner M, Cardell LO: Toll-like receptors in cellular subsets of human tonsil t cells: altered expression during recurrent tonsillitis. Respir Res 2006;7:36.
- Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005;6:68.
- in ’t Veen JC, Grootendorst DC, Bel EH, Smits HH, Van Der Keur M, Sterk PJ, Hiemstra PS: CD11b and L-selectin expression on eosinophils and neutrophils in blood and induced sputum of patients with asthma compared with normal subjects. Clin Exp Allergy 1998;28:606–615.
- Lindemans CA, Kimpen JL, Luijk B, Heidema J, Kanters D, van der Ent CK, Koenderman L: Systemic eosinophil response induced by respiratory syncytial virus. Clin Exp Immunol 2006;144:409–417.
- Bachar O, Adner M, Uddman R, Cardell LO: Toll-like receptor stimulation induces airway hyper-responsiveness to bradykinin, an effect mediated by JNK and NF-ĸB signaling pathways. Eur J Immunol 2004;34:1196–1207.
- Jang BC, Kim DH, Park JW, Kwon TK, Kim SP, Song DK, Park JG, Bae JH, Mun KC, Baek WK, Suh MH, Hla T, Suh SI: Induction of cyclooxygenase-2 in macrophages by catalase: role of NF-ĸB and PI3K signaling pathways. Biochem Biophys Res Commun 2004;316:398–406.
- Tsuchida T, Kawai T, Akira S: Inhibition of IRF3-dependent antiviral responses by cellular and viral proteins. Cell Res 2009;19:3–4.
- Chiba T, Kamada Y, Saito N, Oyamada H, Ueki S, Kobayashi Y, Kayaba H, Chihara J: RANTES and eotaxin enhance CD11b and CD18 expression on eosinophils from allergic patients with eosinophilia in the application of whole blood flow cytometry analysis. Int Arch Allergy Immunol 2005;137(suppl 1):12–16.
- Prussin C, Metcalfe DD: 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486–S494.
- Racz Z: Characteristics of lymphocytes and granulocytes removed from whole blood by buffy coat depletion. Comparison of an automated bottom-and-top processing system and the manual technique. Arch Med Res 2000;31:53–57.
- Kawai T, Akira S: Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008;1143:1–20.
- Sen GC, Sarkar SN: Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev 2005;16:1–14.
- Kenny EF, O’Neill LA: Signalling adaptors used by toll-like receptors: an update. Cytokine 2008;43:342–349.
- Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S: Toll-like receptor signal transduction. Exp Mol Med 2007;39:421–438.
- Nakajima H, Takatsu K: Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007;142:265–273.
- Rosenberg HF, Phipps S, Foster PS: Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007;119:1303–1310; quiz 1311–1312.
- Fransson M, Adner M, Erjefalt J, Jansson L, Uddman R, Cardell LO: Up-regulation of toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir Res 2005;6:100.
- Prussin C, Metcalfe DD: 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2006;117:S450–S456.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.